To evaluate the treatment effect of TEFLARO, an analysis was conducted in 159 patients with ABSSSI in the MITT population. This analysis evaluated responder rates based on achieving both cessation of lesion spread and absence of fever on Study Day 3.
Aztreonam optional if Gram-negative pathogen was identified or suspected.4
No clinically significant differences in ceftaroline AUC were predicted in patients from 12 days to
2 months
postnatal age and with ≥34 weeks of gestational age compared to adults and pediatric patients 2 months of age
and older when given the approved recommended dosage for each patient population.
The use of TEFLARO in pediatric patients ≥34 weeks gestational age and 12 days postnatal age, and older is also supported by evidence from adequate and well-controlled studies of TEFLARO in adults along with additional pharmacokinetic and safety data from pediatric trials. See full Prescribing Information to view the clinical efficacy data in adults.
Learn about TEFLARO dosing in pediatric patients based on age and weight
SEE DOSINGPlease also see full Prescribing Information.
Please also see full Prescribing Information.